Montelukast
Drugmontelukast 5 mg QD 4-weeks.
Other names: MK0476
NCT Number: NCT00756418
A clinical study explores the safety and efficacy of montelukast and to compare the safety and efficacy of montelukast with those of theophylline in pediatric bronchial asthma patients when they are used in conjunction with inhaled steroids.
Looking for future studies?
Notify Me6 year–14 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
montelukast 5 mg QD 4-weeks.
Other names: MK0476
Theophylline 100 to 200 mg BID 4-weeks.
Time frame: Over first 2 Weeks
Organon and Co
Industry
A Randomized Open-Label Comparative Study of Montelukast Versus Theophylline Added to Inhaled Corticosteroid in Pediatric Patients With Bronchial Asthma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01606826
Asthma, Bronchial Diseases
San Francisco, California, United States
View Trial DetailsNCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial DetailsNCT03105843
Asthma, Bronchial Diseases
Kingston, Ontario, Canada
View Trial DetailsNCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial Details